Eprenetapopt (APR-246) is an experimental anti-cancer drug which acts by reactivating certain mutant forms of p53, a tumour-suppressing gene which is commonly mutated into inactive forms as an early step in the development of malignant cancers.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.